On-site inspection of FDA

On September 7, 2021, with the end of the final meeting, Sichuan Qingmu Pharmaceutical Co., Ltd. (hereinafter referred to as Qingmu pharmaceutical), a wholly-owned subsidiary of Chengdu Easton Biopharmaceutical, successfully passed the FDA cGMP on-site inspection.

This FDA on-site inspection is the first time Qingmu pharmaceutical has accepted the cGMP on-site inspection of official drugs in Europe and America, which marks that the company's GMP management has reached an international high level, provides a new opportunity for the company to further expand the American API market, has a positive impact on the expansion of the global API market, and is an important milestone in the company's internationalization strategy, It has important practical significance and strategic value!